IDiyas

For the Inventor, By the Inventor

Waltham, MA, United States of America

Christine Hiu-Tung Chen

USPTO Granted Patents = 16 


 

Average Co-Inventor Count = 10.4

ph-index = 6

Forward Citations = 78(Granted Patents)


Location History:

  • Cambridge, MA (US) (2013 - 2015)
  • Waltham, MA (US) (2011 - 2024)

Company Filing History:

goldMedal16 out of 3,923 
 
Novartis Ag
 patents
silverMedal1 out of 123 
 
Astex Therapeutics Limited
 patents
where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 12209098 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2025-01-28),
2. 11952386 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2024-04-09),
3. 11401259 - 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2022-08-02),
4. 10968235 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2021-04-06),
5. 10774065 - 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2020-09-15),
6. 10336774 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2019-07-02),
7. 10093646 - 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2018-10-09),
8. 10077276 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2018-09-18),
9. RE46942 - 4-piperidinyl compounds for use as tankyrase inhibitors (2018-07-09),
10. 9163003 - 4-piperidinyl compounds for use as tankyrase inhibitors (2015-10-20),
11. 8598217 - Imidazole derivatives and their use as modulators of cyclin dependent kinases (2013-12-03),
12. 8552003 - (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses (2013-10-08),
13. 8546336 - SMAC peptidometics useful as IAP inhibitors (2013-10-01),
14. 8349883 - Hydroxamate-based inhibitors of deacetylases B (2013-01-08),
15. 8044209 - Pyrrolydine derivatives as IAP inhibitors (2011-10-25),

Title: Innovator Spotlight: Christine Hiu-Tung Chen

Introduction: Christine Hiu-Tung Chen is a prominent inventor based in Waltham, Massachusetts, known for her significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 16 patents, she has dedicated her career to developing innovative compounds that have the potential to transform therapeutic approaches.

Latest Patents: Her latest inventions include a focus on N-azaspirocycloalkane substituted N-heteroaryl compounds. These novel compositions are designed for inhibiting the activity of SHP2, showcasing her commitment to addressing complex medical challenges through innovative solutions.

Career Highlights: Throughout her career, Christine has worked with esteemed companies, notably Novartis AG and Astex Therapeutics Limited. Her work at these organizations has been instrumental in advancing drug discovery and development, allowing her to make a lasting impact in the pharmaceutical industry.

Collaborations: Christine has collaborated with skilled individuals such as Zhuoliang Chen and Lawrence Blas Perez, highlighting her ability to work effectively in team environments. These partnerships have enriched her research and have led to several groundbreaking advancements in her field.

Conclusion: Christine Hiu-Tung Chen exemplifies the spirit of innovation through her extensive patent portfolio and impactful collaborations in the pharmaceutical sector. Her ongoing work continues to inspire future generations of inventors and scientists dedicated to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…